{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:06:09Z","timestamp":1791655569916,"version":"4.3.4"},"reference-count":73,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH\/NCI Cancer Center","award":["Support Grant P30 CA008748 (Author ML in part)"],"award-info":[{"award-number":["Support Grant P30 CA008748 (Author ML in part)"]}]},{"name":"NeRRe Therapeutics Ltd","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,1,13]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy of orvepitant (10 or 30\u2009mg given once daily, orally for 4 weeks), a neurokinin-1 receptor antagonist, compared with placebo in reducing the intensity of epidermal growth factor receptor inhibitor (EGFRI)-induced intense pruritus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Randomised, double-blind, placebo-controlled clinical trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>15 hospitals in Italy and five hospitals in the UK.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>44 patients aged \u226518 years receiving an EGFRI for a histologically confirmed malignant solid tumour and experiencing moderate or intense pruritus after EGFRI treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>30 or 10\u2009mg orvepitant or placebo tablets once daily for 4 weeks (randomised 1:1:1).<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary and secondary outcome measures<\/jats:title><jats:p>The primary endpoint was change from baseline in mean patient-recorded numerical rating scale (NRS) score (over the last three recordings) at week 4. Secondary outcome measures were NRS score, verbal rating scale score, Skindex-16 and Leeds Sleep Evaluation Questionnaire at each study visit (baseline, weeks 1, 4, 8); rescue medication use; EGFRI dose reduction; and study withdrawal because of intense uncontrolled pruritus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The trial was terminated early because of recruitment challenges; only 44 of the planned 90 patients were randomised. All patients were analysed for efficacy and safety. Mean NRS score change from baseline to week 4 was \u22122.78 (SD: 2.64) points in the 30\u2009mg group, \u22123.04 (SD: 3.06) points in the 10\u2009mg group and \u22123.21 (SD: 1.77) points in the placebo group; the difference between orvepitant and placebo was not statistically significant. No safety signal was detected. Adverse events related to orvepitant (asthenia, dizziness, dry mouth, hyperhidrosis) were all of mild or moderate severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Orvepitant was safe and well tolerated. No difference in NRS score between the orvepitant and placebo groups was observed at the week 4 primary endpoint. A number of explanations for this outcome are possible.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>EudraCT2013-002763-25.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2019-030114","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T09:54:26Z","timestamp":1581069266000},"page":"e030114","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8222-9025","authenticated-orcid":false,"given":"Bruno","family":"Vincenzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0412-5719","authenticated-orcid":false,"given":"Mike","family":"Trower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3294-616X","authenticated-orcid":false,"given":"Ajay","family":"Duggal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-7786","authenticated-orcid":false,"given":"Pamela","family":"Guglielmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8374-3859","authenticated-orcid":false,"given":"Peter","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4448-8648","authenticated-orcid":false,"given":"David","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-3710","authenticated-orcid":false,"given":"Mario E","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-4695","authenticated-orcid":false,"given":"Emiliangelo","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-8677","authenticated-orcid":false,"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7536-6398","authenticated-orcid":false,"given":"Andrew","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-7786","authenticated-orcid":false,"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"2024052014064454000_10.2.e030114.1","doi-asserted-by":"publisher","DOI":"10.1159\/000112795"},{"key":"2024052014064454000_10.2.e030114.2","first-page":"149","article-title":"Dermatologic toxicities of targeted anticancer therapies","volume":"8","author":"Balagula","year":"2010","journal-title":"J Support Oncol"},{"key":"2024052014064454000_10.2.e030114.3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dth.12027","article-title":"Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4","volume":"26","author":"Fischer","year":"2013","journal-title":"Dermatol Ther"},{"key":"2024052014064454000_10.2.e030114.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1197-6"},{"key":"2024052014064454000_10.2.e030114.5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00520-015-2781-y","article-title":"Xerosis and pruritus as major EGFRI-associated adverse events","volume":"24","author":"Clabbers","year":"2016","journal-title":"Support Care Cancer"},{"key":"2024052014064454000_10.2.e030114.6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25090"},{"key":"2024052014064454000_10.2.e030114.7","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0021-0"},{"key":"2024052014064454000_10.2.e030114.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70373-X"},{"key":"2024052014064454000_10.2.e030114.9","unstructured":"AstraZeneca Pharmaceuticals LP . Tagrisso [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2015."},{"key":"2024052014064454000_10.2.e030114.10","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2008.n.040"},{"key":"2024052014064454000_10.2.e030114.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0769-1"},{"key":"2024052014064454000_10.2.e030114.12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2340\/00015555-3129","article-title":"Pruritus in patients under targeted anticancer therapy: a multidimensional analysis using the 5-D itch scale","volume":"99","author":"Cho","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"2024052014064454000_10.2.e030114.13","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00520-010-0999-2","article-title":"How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?","volume":"19","author":"Chan","year":"2011","journal-title":"Support Care Cancer"},{"key":"2024052014064454000_10.2.e030114.14","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00031.2013"},{"key":"2024052014064454000_10.2.e030114.15","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.813932"},{"key":"2024052014064454000_10.2.e030114.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.09.023"},{"key":"2024052014064454000_10.2.e030114.17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJMc1013027","article-title":"More on aprepitant for erlotinib-induced pruritus","volume":"364","author":"Gerber","year":"2011","journal-title":"N Engl J Med"},{"key":"2024052014064454000_10.2.e030114.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(01)00031-0"},{"key":"2024052014064454000_10.2.e030114.19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaci.2016.12.980","article-title":"Substance P activates Mas-related G protein-coupled receptors to induce itch","volume":"140","author":"Azimi","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2024052014064454000_10.2.e030114.20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000446011","article-title":"Central mechanisms of itch","volume":"50","author":"Carstens","year":"2016","journal-title":"Curr Probl Dermatol"},{"key":"2024052014064454000_10.2.e030114.21","doi-asserted-by":"publisher","DOI":"10.1097\/WNR.0b013e328337310a"},{"key":"2024052014064454000_10.2.e030114.22","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000172"},{"key":"2024052014064454000_10.2.e030114.23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.neuron.2018.11.010","article-title":"Tac1-Expressing neurons in the periaqueductal gray facilitate the Itch-Scratching cycle via descending regulation","volume":"101","author":"Gao","year":"2019","journal-title":"Neuron"},{"key":"2024052014064454000_10.2.e030114.24","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12515092"},{"key":"2024052014064454000_10.2.e030114.25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2340\/0001555571291295","article-title":"Reactions to intradermally injected substance P and topically applied mustard oil in atopic dermatitis patients","volume":"71","author":"Heyer","year":"1991","journal-title":"Acta Derm Venereol"},{"key":"2024052014064454000_10.2.e030114.26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04722.x"},{"key":"2024052014064454000_10.2.e030114.27","first-page":"1140","article-title":"Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice","volume":"286","author":"Andoh","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"2024052014064454000_10.2.e030114.28","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/exd.12528","article-title":"Neurokinin-1 receptor antagonist orvepitant is an effective inhibitor of itch-associated response in a Mongolian gerbil model of scratching behaviour","volume":"23","author":"Trower","year":"2014","journal-title":"Exp Dermatol"},{"key":"2024052014064454000_10.2.e030114.29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/exd.12656","article-title":"The NK1 receptor antagonist aprepitant attenuates NK1 agonist-induced scratching behaviour in the gerbil after intra-dermal, topical or oral administration","volume":"24","author":"Costantini","year":"2015","journal-title":"Exp Dermatol"},{"key":"2024052014064454000_10.2.e030114.30","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.intimp.2006.06.002","article-title":"A new chronic itch model accompanied by skin lesions in hairless mice","volume":"6","author":"Ueda","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"2024052014064454000_10.2.e030114.31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-3-662-44605-8_14","article-title":"Nk-1 antagonists and itch","volume":"226","author":"St\u00e4nder","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"2024052014064454000_10.2.e030114.32","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S , Yosipovitch G . Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus. Br J Dermatol 2019.","DOI":"10.1111\/bjd.18496"},{"key":"2024052014064454000_10.2.e030114.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010968","article-title":"Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy","volume":"5","author":"St\u00e4nder","year":"2010","journal-title":"PLoS One"},{"key":"2024052014064454000_10.2.e030114.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0906670"},{"key":"2024052014064454000_10.2.e030114.35","first-page":"665","article-title":"Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma","volume":"164","author":"Booken","year":"2011","journal-title":"Br J Dermatol"},{"key":"2024052014064454000_10.2.e030114.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.01.016"},{"key":"2024052014064454000_10.2.e030114.37","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/j.jaad.2012.02.008","article-title":"Aprepitant: a novel neurokinin-1 receptor\/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma","volume":"67","author":"Ladizinski","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2024052014064454000_10.2.e030114.38","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00520-010-0895-9","article-title":"Aprepitant against pruritus in patients with solid tumours","volume":"18","author":"Vincenzi","year":"2010","journal-title":"Support Care Cancer"},{"key":"2024052014064454000_10.2.e030114.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1003937"},{"key":"2024052014064454000_10.2.e030114.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1009698"},{"key":"2024052014064454000_10.2.e030114.41","first-page":"487","article-title":"More on aprepitant for erlotinib-induced pruritus","volume":"364","author":"Mir","year":"2011","journal-title":"N Engl J Med"},{"key":"2024052014064454000_10.2.e030114.42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMc1003937","article-title":"Aprepitant for erlotinib-induced pruritus","volume":"364","author":"Vincenzi","year":"2010","journal-title":"N Engl J Med"},{"key":"2024052014064454000_10.2.e030114.43","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamadermatol.2013.170","article-title":"The use of aprepitant in brachioradial pruritus","volume":"149","author":"Ally","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2024052014064454000_10.2.e030114.44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5021\/ad.2016.28.1.124","article-title":"Treatment for refractory pruritus using oral aprepitant","volume":"28","author":"Huh","year":"2016","journal-title":"Ann Dermatol"},{"key":"2024052014064454000_10.2.e030114.45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/dth.12113","article-title":"Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant","volume":"27","author":"Jim\u00e9nez Gallo","year":"2014","journal-title":"Dermatol Ther"},{"key":"2024052014064454000_10.2.e030114.46","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ad.2013.07.007","article-title":"Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma","volume":"105","author":"Borja-Consigliere","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"2024052014064454000_10.2.e030114.47","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3194-8","article-title":"Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature","volume":"17","author":"Song","year":"2017","journal-title":"BMC Cancer"},{"key":"2024052014064454000_10.2.e030114.48","doi-asserted-by":"crossref","first-page":"54","DOI":"10.21037\/atm.2019.01.02","article-title":"Aprepitant for gefitinib-induced refractory pruritus in Chinese malignancy population","volume":"7","author":"Qin","year":"2019","journal-title":"Ann. Transl. Med"},{"key":"2024052014064454000_10.2.e030114.49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000493256","article-title":"Need for flexible adjustment of the treatment schedule for aprepitant administration against erlotinib-induced refractory pruritus and skin rush","volume":"12","author":"Seki","year":"2019","journal-title":"Case Rep Oncol"},{"key":"2024052014064454000_10.2.e030114.50","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.critrevonc.2015.05.007","article-title":"Risk of pruritus in cancer patients treated with biological therapies: a systematic review and meta-analysis of clinical trials","volume":"96","author":"Santoni","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024052014064454000_10.2.e030114.51","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1016\/j.bmc.2013.09.001","article-title":"Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate","volume":"21","author":"Di Fabio","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"2024052014064454000_10.2.e030114.52","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.124958"},{"key":"2024052014064454000_10.2.e030114.53","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.2.536"},{"key":"2024052014064454000_10.2.e030114.54","doi-asserted-by":"publisher","DOI":"10.1126\/science.281.5383.1640"},{"key":"2024052014064454000_10.2.e030114.55","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113480990"},{"key":"2024052014064454000_10.2.e030114.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.02.007"},{"key":"2024052014064454000_10.2.e030114.57","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1246"},{"key":"2024052014064454000_10.2.e030114.58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","article-title":"The Skindex instruments to measure the effects of skin disease on quality of life","volume":"30","author":"Chren","year":"2012","journal-title":"Dermatol Clin"},{"key":"2024052014064454000_10.2.e030114.59","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0298"},{"key":"2024052014064454000_10.2.e030114.60","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.chest.2019.08.001","article-title":"The neurokinin-1 receptor antagonist Orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot study (VOLCANO-1)","volume":"157","author":"Smith","year":"2020","journal-title":"Chest"},{"key":"2024052014064454000_10.2.e030114.61","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/jid.2014.522","article-title":"Placebo effects on itch: a meta-analysis of clinical trials of patients with dermatological conditions","volume":"135","author":"van Laarhoven","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2024052014064454000_10.2.e030114.62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005773","article-title":"Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy","volume":"5","author":"Mascia","year":"2013","journal-title":"Sci Transl Med"},{"key":"2024052014064454000_10.2.e030114.63","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0305"},{"key":"2024052014064454000_10.2.e030114.64","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/j.pain.0000000000001220","article-title":"Alloknesis and hyperknesis\u2014mechanisms, assessment methodology, and clinical implications of itch sensitization","volume":"159","author":"Andersen","year":"2018","journal-title":"Pain"},{"key":"2024052014064454000_10.2.e030114.65","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.62.2.212"},{"key":"2024052014064454000_10.2.e030114.66","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/13543784.2019.1638910","article-title":"The NK1 receptor antagonist serlopitant for treatment of chronic pruritus","volume":"28","author":"St\u00e4nder","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"2024052014064454000_10.2.e030114.67","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaad.2018.02.030","article-title":"Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial","volume":"78","author":"Yosipovitch","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024052014064454000_10.2.e030114.68","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","article-title":"Serlopitant reduced pruritus in patients with Prurigo nodularis in a phase 2, randomized, placebo-controlled trial","volume":"80","author":"St\u00e4nder","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024052014064454000_10.2.e030114.69","unstructured":"Vanda Pharmaceuticals Inc . Vanda's tradipitant improves itch and disease severity in patients with atopic dermatitis, 2017. Available: https:\/\/vandapharmaceuticalsinc.gcs-web.com\/node\/8091\/pdf [Accessed 28 Aug 2019]."},{"key":"2024052014064454000_10.2.e030114.70","unstructured":"U.S. National Library of Medicine . study of the efficacy, safety and tolerability of serlopitant for the treatment of pruritus (itch) with plaque psoriasis, 2019. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03343639?term=MTI-109&rank=1 [Accessed 28 Aug 2019]."},{"key":"2024052014064454000_10.2.e030114.71","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2217\/fon-2018-0187","article-title":"Management and grading of EGFR inhibitor-induced cutaneous toxicity","volume":"14","author":"Beech","year":"2018","journal-title":"Future Oncol"},{"key":"2024052014064454000_10.2.e030114.72","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2013.06.038","article-title":"Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis","volume":"69","author":"Ensslin","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2024052014064454000_10.2.e030114.73","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/era.13.30","article-title":"Dermatologic adverse events associated with afatinib: an oral ErbB family blocker","volume":"13","author":"Lacouture","year":"2013","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-030114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T21:07:26Z","timestamp":1716239246000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-030114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,6]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/bmjopen-2019-030114"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-030114","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}